(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 November 2020 (05.11.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/223537 A8

(51) International Patent Classification:
C07K 14/725 (2006.01) *C07K 16/32* (2006.01)
C07K 14/73 (2006.01) *C12N 5/0783* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2020/030818

(22) International Filing Date:
30 April 2020 (30.04.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/841,753 01 May 2019 (01.05.2019) US
62/841,748 01 May 2019 (01.05.2019) US

(71) Applicant: **PACT PHARMA, INC.** [US/US]; 2 Corporate Drive, South San Francisco, CA 94080 (US).

(72) Inventors: **SENNINO, Barbara**; c/o PACT PHARMA, INC., 2 Corporate Drive, South San Francisco, CA 94080 (US). **JACOBY, Kyle**; c/o PACT PHARMA, INC., 2 Corporate Drive, South San Francisco, CA 94080 (US). **MANDL-CASHMAN, Stefanie**; c/o PACT PHARMA, INC., 2 Corporate Drive, South San Francisco, CA 94080 (US). **DUBREUIL, Michael, M.**; c/o PACT PHARMA, INC., 2 Corporate Drive, South San Francisco, CA 94080 (US). **GAGNON, John**; c/o PACT PHARMA, INC., 2 Corporate Drive, South San Francisco, CA 94080 (US). **FRANZUSOFF, Alex**; c/o PACT PHARMA, INC., 2 Corporate Drive, South San Francisco, CA 94080 (US).

(74) Agent: **LENDARIS, Steven, P.** et al.; Baker Botts LLP, 30 Rockefeller Plaza, New York, NY 10112-4498 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY




FIGURE 17B

(57) Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct. In certain embodiments, the presently disclosed subject matter provides a cell, comprising an exogenous T cell receptor (TCR), and an exogenous CD8. In certain embodiments, the exogenous CD8 comprises at least one monomer. In certain embodiments, the at least one monomer of the exogenous CD8 comprises an extracellular domain, a transmembrane domain, an intracellular domain, fragments thereof, or combinations thereof.

[Continued on next page]

WO 2020/223537 A8

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(48) **Date of publication of this corrected version:**
11 November 2021 (11.11.2021)

(15) **Information about Correction:**
see Notice of 11 November 2021 (11.11.2021)